Deva Holding AS Asset Resilience Ratio
Deva Holding AS asset resilience ratio. Deva Holding AS (DEVA) has an Asset Resilience Ratio of 2.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Deva Holding AS defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Deva Holding AS (2005–2024)
Asset resilience ratio of Deva Holding AS from 2005 to 2024. This chart shows how Deva Holding AS's Asset Resilience Ratio has changed over time. Read Deva Holding AS debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Deva Holding AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Deva Holding AS.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0% |
| Short-term Investments | TL745.77 Million | 2.1% |
| Total Liquid Assets | TL745.77 Million | 2.10% |
Asset Resilience Insights
- Limited Liquidity: Deva Holding AS maintains only 2.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Deva Holding AS Industry Peers by Asset Resilience Ratio
Compare Deva Holding AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Deva Holding AS Asset Resilience Ratio by Year (2005–2024)
Deva Holding AS asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Deva Holding AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.06% | TL1.21 Billion ≈ $27.01 Million |
TL29.73 Billion ≈ $665.86 Million |
-5.05pp |
| 2023-12-31 | 9.11% | TL2.95 Billion ≈ $66.10 Million |
TL32.40 Billion ≈ $725.77 Million |
+0.59pp |
| 2022-12-31 | 8.52% | TL734.62 Million ≈ $16.45 Million |
TL8.62 Billion ≈ $193.16 Million |
-4.19pp |
| 2019-12-31 | 12.70% | TL269.26 Million ≈ $6.03 Million |
TL2.12 Billion ≈ $47.47 Million |
+12.70pp |
| 2018-12-31 | 0.01% | TL86.10K ≈ $1.93K |
TL1.67 Billion ≈ $37.37 Million |
-0.01pp |
| 2008-12-31 | 0.01% | TL73.00K ≈ $1.64K |
TL489.79 Million ≈ $10.97 Million |
-0.05pp |
| 2006-12-31 | 0.06% | TL177.00K ≈ $3.96K |
TL290.88 Million ≈ $6.52 Million |
+0.05pp |
| 2005-12-31 | 0.01% | TL30.00K ≈ $671.92 |
TL273.18 Million ≈ $6.12 Million |
-- |
About Deva Holding AS
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more